Introduction
In a recent interview with the Anatomical and Molecular Pathology Lab at Sydpath, St. Vincent Hospital, Senior Staff Specialist Dr. Tao Yang and Senior Hospital Scientist
Dr. Bin Wang shared valuable insights into the significant advancements made in therapeutic pathway selection with next-generation sequencing (NGS).
The lab, located in Sydney, NSW, Australia, has become a major cancer testing center for the country, receiving tumor specimens from more than 15 hospitals and centers across Sydney and regional New South Wales. With the introduction of an NGS platform, the lab has experienced rapid growth in testing demand and has been able to provide a comprehensive view of molecular markers to facilitate treatment selections.
Adding Value to Cancer Treatment Selection:
Dr. Tao Yang highlighted the crucial role of NGS technology in detecting treatable biomarkers. NGS allows for the evaluation of tens or hundreds of genes simultaneously using the same tissue sample may reduce the need from patients, providing a wealth of information in a single test. This not only reduces the need for repeat biopsies but also enables the laboratory to inform the multidisciplinary team about effective treatment options for patients.
Challenges and Achievements:
The rapid development of new biomarkers and drugs presents both challenges and achievements for the laboratory. As a clinical diagnostic laboratory, accuracy, speed, and regulatory compliance are of utmost importance. Dr. Yang emphasized the need to stay up-to-date with current and future developments to provide the best possible service to patients.
Expanding Access to NGS Testing:
NGS has the potential to become the standard of care for cancer patients, offering new possibilities for targeted therapy. Dr. Yang expressed the desire for every cancer patient to have the opportunity to have their tumor tissue tested using NGS technology. The ability to identify biomarker alterations opens doors to potential treatments, including clinical trials and effective medicines. Next-generation sequencing technology has been instrumental in providing hope and more informed treatment options for patients.
Conclusion:
The integration of a NGS platform has enhanced therapeutic pathway selection at the cancer genetic lab at Sydpath, St. Vincent Hospital. The insights shared by Dr. Wang and Dr. Yang emphasize the value of NGS technology in detecting treatable biomarkers and offering new treatment possibilities.
The future holds great promise as the lab plans to expand its testing capabilities and continue to improve patient care. The lab aims to provide every patient with the best possible treatment options and contribute to the advancements in cancer care on a global scale.
To learn more about precision oncology and the role of next-generation sequencing, visit oncomine.com/precision-oncology.
Case Number: 55417 0724
In everyday practice, it is common for pathology labs to evaluate >50% cytological specimens across solid tumors especially in lung and pancreatic cancers. Many of these cytological specimens require molecular profiling to help confirm diagnoses and...
How can we enhance the clinical utility and accessibility of liquid biopsy NGS?
Liquid biopsy next-generation sequencing (NGS) holds great promise in therapy selection for oncology, offering non-invasive and real-time insights into tumor genetics,”...
Introduction
In a recent interview with the Anatomical and Molecular Pathology Lab at Sydpath, St. Vincent Hospital, Senior Staff Specialist Dr. Tao Yang and Senior Hospital ScientistDr. Bin Wang shared valuable insights into the significant...